[3H]Ro 15-1788 binding sites to brain membrane of the saltwater Mugil cephalus.
The equilibrium binding parameters of the benzodiazepine antagonist [3H]Ro 15-1788 (8-fluoro-3-carboethoxy-5,6-dihydro-5-methyl-6-oxo-4H-imidazol-[1,5-a]-1,4 benzodiazepine) were evaluated in brain membranes of the saltwater teleost fish, Mugil cephalus. To test receptor subtype specificity, displacement studies were carried out by competitive binding of [3H]Ro 15-1788 against six benzodiazepine receptor ligands, flunitrazepam [5-(2-fluoro-phenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one], alpidem [N,N-dipropyl-6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridine-3-acetamide], zolpidem [N,N-6 trimethyl-2-(4-methyl-phenyl)imidazo[1,2-a]pyridine-3-acetamide hemitartrate], and beta-CCM (methyl beta-carboline-3-carboxylate). Saturation studies showed that [3H]Ro 15-1788 bound saturatably, reversibly and with a high affinity to a single class of binding sites (Kd value of 1.18-1.5 nM and Bmax values of 124-1671 fmol/mg of protein, depending on brain regions). The highest concentration of benzodiazepine recognition sites labeled with [3H]Ro 15-1788 was present in the optic lobe and the olfactory bulb and the lowest concentration was found in the medulla oblongata, cerebellum and spinal cord. The rank order of displacement efficacy of unlabelled ligands observed suggested that central-type benzodiazepine receptors are present in one class of binding sites (Type I-like) in brain membranes of Mugil cephalus. Moreover, the uptake of 36Cl- into M. cephalus brain membrane vesicles was only marginally stimulated by concentrations of GABA that significantly enhanced the 36Cl- uptake into mammalian brain membrane vesicles. The results may indicate a different functional activity of the GABA-coupled chloride ionophore in the fish brain as compared with the mammalian brain.
Betti
L
L
Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie dell'Università di Pisa, Sez. Via Bonanno 6, 56100, Pisa, Italy.
Giannaccini
G
G
Gori
M
M
Bistocchi
M
M
Lucacchini
A
A
D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism*; D002243:Carbolines / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D002712:Chlorides / Q000378:metabolism; D003975:Diazepam / Q000037:antagonists & inhibitors; D005260:Female; D005399:Fishes / Q000378:metabolism*; D005442:Flumazenil / Q000378:metabolism*; D005445:Flunitrazepam / Q000378:metabolism; D007093:Imidazoles / Q000378:metabolism; D007476:Ionophores / Q000378:metabolism; D008297:Male; D011725:Pyridines / Q000378:metabolism; D011963:Receptors, GABA-A / Q000378:metabolism; D013574:Synaptosomes / Q000378:metabolism*; D014316:Tritium; D000077334:Zolpidem; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D002243:Carbolines; D002712:Chlorides; D007093:Imidazoles; D007476:Ionophores; D011725:Pyridines; D011963:Receptors, GABA-A; D014316:Tritium; D005442:Flumazenil; D005680:gamma-Aminobutyric Acid; D005445:Flunitrazepam; D000077334:Zolpidem; C036150:beta-carboline-3-carboxylic acid methyl ester; C052036:alpidem; D003975:Diazepam